glp 1 news GLP-1 weight loss drugs leave users low on key nutrients, study finds Health insurer Cigna will stop

This is not just about looking cute in a bikini somewhere, she says

Clinicians should exercise caution in patients with a history of pancreatitis or gastroparesis, inflammatory bowel disease, other gut motility disorders, medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, and pause therapy when clinically indicated, such as before anesthesia

As patients lose weight and metabolic control improves, clinicians should reassess concurrent therapies to reduce the risk of hypoglycemia and polypharmacy, particularly when insulin or sulfonylureas are used

Overall, the selected trials had a low to moderate risk of bias

We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology. In two other clinical trials, funded by pharmaceutical companies, which were not included in the meta-analysis due to methodological differences, the drug responses were similar between carriers and non-carriers

This is important news because it means these medications can help a wide range of patients achieve their health goals